Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

News Conference News ACC 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

March 11, 2018

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Live From Washington: ACC 2017, Day Three

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

March 19, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Conference News ACC 2013

Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting

Yael L. Maxwell

March 08, 2013

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

March 26, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.